Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps
So its been studied in inflammatory bowel diseases like Crohns disease and ulcerative colitis, ankylosing spondylitis, multiple sclerosis, lupus, psoriasis, lichen planus, type 1 diabetes, and Hashimotos [disease], fibrositis
Song WJ, Seshadri M, Ashraf U, Mdluli T, Mondal P, Keil M, Azevedo M, Kirschner LS, Stratakis CA, and Hussain MA
Cancers , 15(3), 910
When weight reduction exceeds approximately 1.5 kg per week during early therapy, clinicians should remain alert
Key Players in the GLP-1 Drugs Market Novo Nordisk has been at the forefront of GLP-1 drug development